
Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.
Raloxifene hydrochloride (Evista) is indicated for the treatment and prevention of osteoporosis in postmenopausal women, as well as to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis.
Medication Pearl of the Day: Evista (raloxifene hydrochloride)
Indication: Raloxifene hydrochloride (Evista) is an estrogen agonist/antagonist indicated for the treatment and prevention of osteoporosis in postmenopausal women, as well as to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis.
Insight:
Source:




